The US Food and Drug Administration has approved Jakafi (ruxolitinib) for myelofibrosis. The drug is a JAK inhibitor which is designed to block the JAK1 and 2 enzymes which are involved in regulating blood and immunological functioning. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
